Information  X 
Enter a valid email address

MaxCyte, Inc. (MXCT)

  Print      Mail a friend

Wednesday 31 October, 2018

MaxCyte, Inc.

Result of AGM

RNS Number : 9281F
MaxCyte, Inc.
31 October 2018
 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Result of AGM

 

Gaithersburg, MD - 31 October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that at its Annual General Meeting held today at 11:00 EDT, all resolutions were duly passed.

 

 

For further information, please contact:

 

MaxCyte Inc.


Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

+1 301 944 1660

 

 

Nominated Adviser and Broker

Panmure Gordon


Emma Earl

Freddy Crossley

Ryan McCarthy

 

Corporate Broking

James Stearns

+44 (0) 20 7886 2500

 

 

Financial PR Adviser

Consilium Strategic Communications


Mary-Jane Elliott

Chris Welsh

Sukaina Virji

+44 (0)203 709 5700

[email protected]

 

 

About MaxCyte

 

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGBLBDGDDXBGIB

a d v e r t i s e m e n t